Companies › SymBio Pharmaceuticals
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Infectious disease; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Brincidofovir DNA polymerase inhibitor | DNA | Phase 3 | Adenovirus Infections; Progressive Multifocal Leukoencephalopathy | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07387367 | Brincidofovir | Phase 3 | Adenovirus Infections | Infectious disease | Jan 2028 |
| NCT07511049 | Brincidofovir | Phase 2 | Progressive Multifocal Leukoencephalopathy | Infectious disease | Dec 2029 |
–
TCM Biotech International Vivacelle Bio Ansun Biopharma F2G Baxis Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.